Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Plenaxis; Germany: Plenaxis; Netherlands: Plenaxis.

Drug combinations


Abarelix: C~72~H~95~ClN~14~O~14~. Mw: 1416.06. N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N^6^-isopropyl-L-lysyl-L-prolyl-D-alaninamide. CAS-183552-38-7 (1997).

Pharmacologic Category

Antineoplastic Agents; Endocrine Therapy; Gonadotropin Releasing Hormone Antagonists. (ATC-Code: L02BX01).

Mechanism of action

Therapeutic use

Palliative treatment of advanced symptomatic prostate cancer.

Pregnancy and lactiation implications

Should not be used in women.

Unlabeled use


Hypersensitivity to abarelix or any ingredient in the formulation. Not indicated in women or pediatric patients.

Warnings and precautions

Risk of allergic reactions. May cause fetal harm. Increases in serum AST (SGOT) or ALT (SGPT) concentrations. Prolongation of QTc interval. Risk of decreased bone mineral density following chronic therapy with GnRH antagonists and agonists.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart